Shots:

• The companies temporarily paused enrollment in the P-II clinical study to evaluate the combination treatment regimen of islatravir and lenacapavir in a ratio (2:1) in 75 patients aged ≥18yrs. with HIV who are virologically suppressed on antiretroviral therapy
• This pause will allow the companies to consider potential protocol adjustments following Merck's recent decision to stop the dosing due to safety concerns in the P-II IMAGINE-DR trial to evaluate the combination of MK-8507 and islatravir
• Additionally, participants who were enrolled in the P-II study will continue to receive the study drug and be monitored per the current protocol

Click here to­ read full press release |

Ref: Gilead | Image: Gilead